1. Dyck PJ, Chance P, Lebo R, Carney JA. Dyck PJ, Thomas PK, Griffin JW, Low PA Poduslo JF, editors. Hereditary motor and sensory neuropathies. Peripheral neuropathy. 1993. 3rd edn. Philadelphia: WB Saunders;1094–1136.
2. Berger P, Young P, Suter U. Molecular cell biology of Charcot-Marie-Tooth disease. Neurogenetics. 2002. 4:1–15.
Article
3. Charcot J, Marie P. Sue une forme particulaire d'atrophie musculaire progressive souvent familial debutant par les pieds et les jamber et atteingnant plus tard les mains. Rev Med. 1886. 6:97–138.
4. Tooth H. The peroneal type of progressive muscular atrophy. 1886. London: Lewis.
5. Shy ME, Garbern JY, Kamholz J. Hereditary motor and sensory neuropathies: a biological perspective. Lancet Neurol. 2002. 1:110–118.
Article
6. Shy ME. Charcot-Marie-Tooth disease: an update. Curr Opin Neurol. 2004. 17:579–585.
Article
7. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain. 1980. 103:259–280.
Article
8. Lobsiger CS, Taylor V, Suter U. The early life of a Schwann cell. Biol Chem. 2002. 383:245–253.
Article
9. Suter U, Scherer SS. Disease mechanisms in inherited neuropathies. Nat Rev Neurosci. 2003. 4:714–726.
Article
10. Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med. 2003. 9:1533–1537.
Article
11. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004. 10:396–401.
Article
12. Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology. 2005. 65:681–689.
Article
13. Martini R. The effect of myelinating Schwann cells on axons. Muscle Nerve. 2001. 24:456–466.
Article
14. Huxley C, Passage E, Manson A, Putzu G, Figarella-Branger D, Pellissier JF, et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet. 1996. 5:563–569.
Article
15. Lupski JR. Charcot-Marie-Tooth disease: a gene-dosage effect. Hosp Pract (Minneap). 1997. 32:83–84. 89–91. 94–95.
Article
16. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991. 66:219–232.
Article
17. Boerkoel CF, Takashima H, Garcia CA, Olney RK, Johnson J, Berry K, et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol. 2002. 51:190–201.
Article
18. Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B, et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell. 1993. 72:143–151.
Article
19. Young P, Wiebusch H, Strogbauer F, Ringelstein B, Assmann G, Funke H. A novel frameshift mutation in
PMP22 accounts for hereditary neuropathy with liability to pressure palsies. Neurology. 1997. 48:450–452.
Article
20. Nicholson GA, Valentijn LJ, Cherryson AK, Kennerson ML, Bragg TL, DeKroon RM, et al. A frame shift mutation in the
PMP22 gene in hereditary neuropathy with liability to pressure palsies. Nat Genet. 1994. 6:263–266.
Article
21. Sereda M, Griffiths I, Puhlhofer A, Stewart H, Rossner MJ, Zimmerman F, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron. 1996. 16:1049–1060.
Article
22. Behse F, Buchthal F, Carlsen F, Knappeis GG. Hereditary neuropathy with liability to pressure palsies. Electrophysiological and histopathological aspects. Brain. 1972. 95:777–794.
Article
23. Verhagen WI, Gabreels-Festen AA, van Wensen PJ, Joosten EM, Vingerhoets HM, Gabreels FJ, et al. Hereditary neuropathy with liability to pressure palsies: a clinical, electroneurophysiological and morphological study. J Neurol Sci. 1993. 116:176–184.
Article
24. Le Guern E, Sturtz F, Gugenheim M, Gouider R, Bonnebouche C, Ravise N, et al. Detection of deletion within 17p11.2 in 7 French families with hereditary neuropathy with liability to pressure palsies (HNPP). Cytogenet Cell Genet. 1994. 65:261–264.
Article
25. Mariman FC, Sillekens PT, van Beek-Reinders, van Venrooij WJ. A model for the excision of introns 1 and 2 from adenoviral major late pre-messenger RNAs. J Mol Biology. 1984. 178:47–62.
Article
26. Gouider R, LeGuern E, Emile J, Tardieu S, Cabon F, Samid M, et al. Hereditary neuralgic amyotrophy and hereditary neuropathy with liability to pressure palsies: two distinct clinical, electrophysiologic, and genetic entities. Neurology. 1994. 44:2250–2252.
Article
27. Pareyson D, Scaioli V, Taroni F, Botti S, Lorenzetti D, Solari A, et al. Phenotypic heterogeneity in hereditary neuropathy with liability to pressure palsies associated with chromosome 17p11.2-12 deletion. Neurology. 1996. 46:1133–1137.
Article
28. Kim SM, Chung KW, Choi BO, Yoon ES, Choi JY, Park KD, et al. Hereditary neuropathy with liability to pressure palsies (HNPP) patients of Korean ancestry with chromosome 17p11.2-p12 deletion. Exp Mol Med. 2004. 36:28–35.
Article
29. Roa BB, Garcia CA, Suter U, Kulpa DA, Wise CA, Mueller J, et al. Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the
PMP22 gene. N Engl J Med. 1993. 329:96–101.
Article
30. Roa BB, Dyck PJ, Marks HG, Chance PF, Lupski JR. Déjérine-Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (
PMP22) gene. Nat Genet. 1993. 5:269–273.
Article
31. Choi BO, Chung KW, Park KD, Choi KG, Kim SM, Kim Y, et al. Charcot-Marie-Tooth type 1A patient with a novel frame shift mutation (Ala106fs) in the PMP22 gene. J Korean Neurol Assoc. 2004. 22:673–676.
32. Timmerman V, De Jonghe P, Ceuterick C, De Vriendt E, Lofgren A, Nelis E, et al. Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology. 1999. 52:1827–1832.
Article
33. Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet. 1998. 18:382–384.
Article
34. Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chennoufi AB, Seitanidou T, et al. Krox-20 controls myelination in the peripheral nervous system. Nature. 1994. 371:796–799.
Article
35. Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J. EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron. 2001. 30:355–368.
Article
36. Chung KW, Sunwoo IN, Kim SM, Park KD, Kim WK, Kim TS, et al. Two missense mutations of EGR2 R359W and GJB1 V136A in a Charcot-Marie-Tooth disease family. Neurogenetics. 2005. 6:159–163.
Article
37. Musso M, Balestra P, Bellone E, Cassandrini D, Di Maria E, Doria LL, et al. The D355V mutation decreases
EGR2 binding to an element within the
Cx32 promoter. Neurobiol Dis. 2001. 8:700–706.
Article
38. Warner LE, Svaren J, Milbrandt J, Lupski JR. Functional consequences of mutations in the early growth response 2 gene (
EGR2) correlate with severity of human myelinopathies. Hum Mol Genet. 1999. 8:1245–1251.
Article
39. Tang X, Fenton MJ, Amar S. Identification and functional characterization of a novel binding site on TNF-alpha promoter. Proc Natl Acad Sci U S A. 2003. 100:4096–4101.
Article
40. Moriwaki Y, Begum NA, Kobayashi M, Matsumoto M, Toyoshima K, Seya T. Mycobacterium bovis Bacillus Calmette-Guerin and its cell wall complex induce a novel lysosomal membrane protein, SIMPLE, that bridges the missing link between lipopolysaccharide and p53-inducible gene,
LITAF (PIG7), and estrogen-inducible gene,
EET-1. J Biol Chem. 2001. 276:23065–23076.
Article
41. Guilbot A, Williams A, Ravise N, Verny C, Brice A, Sherman DL, et al. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet. 2001. 10:415–421.
Article
42. Gillespie CS, Sherman DL, Blair GE, Brophy PJ. Periaxin, a novel protein of myelinating Schwann cells with a possible role in axonal ensheathment. Neuron. 1994. 12:497–508.
Article
43. Sherman DL, Brophy PJ. A tripartite nuclear localization signal in the PDZ-domain protein L-periaxin. J Biol Chem. 2000. 275:4537–4540.
Article
44. Scherer SS, Xu YT, Bannerman PG, Sherman DL, Brophy PJ. Periaxin expression in myelinating Schwann cells: modulation by axon-glial interactions and polarized localization during development. Development. 1995. 121:4265–4273.
Article
45. Kijima K, Numakura C, Shirahata E, Sawaishi Y, Shimohata M, Igarashi S, et al. Periaxin mutation causes early-onset but slow-progressive Charcot-Marie-Tooth disease. J Hum Genet. 2004. 49:376–379.
Article
46. Bolino A, Muglia M, Conforti FL, LeGuern E, Salih MA, Georgiou DM, et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularinrelated protein-2. Nat Genet. 2000. 25:17–19.
Article
47. Laporte J, Blondeau F, Buj-Bello A, Mandel JL. The myotubularin family: from genetic disease to phosphoinositide metabolism. Trends Genet. 2001. 17:221–228.
Article
48. Gambardella A, Bono F, Muglia M, Valentino P, Quattrone A. Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths (CMT4B). Ann NY Acad Sci. 1999. 883:47–55.
Article
49. Senderek J, Bergmann C, Weber S, Ketelsen UP, Schorle H, Rudnik-Schoneborn S, et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet. 2003. 12:349–356.
Article
50. Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004. 36:449–451.
Article
51. Kijima K, Numakura C, Izumino H, Umetsu K, Nezu A, Shiiki T, et al. Mitochondrial GTPase mitofusin 2 mutation in Charcot-Marie-Tooth neuropathy type 2A. Hum Genet. 2005. 116:23–27.
Article
52. Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology. 2005. 65:197–204.
Article
53. Rojo M, Legros F, Chateau D, Lombes A. Membrane topology and mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the transmembrane GTPase Fzo. J Cell Sci. 2002. 115:1663–1674.
Article
54. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003. 160:189–200.
Article
55. Koshiba T, Detmer SA, Kaiser JT, Chen H, McCaffery JM, Chan DC. Structural basis of mitochondrial tethering by mitofusin complexes. Science. 2004. 305:858–862.
Article
56. Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem. 2005. 280:26185–26192.
Article
57. Honda S, Aihara T, Hontani M, Okubo K, Hirose S. Mutational analysis of action of mitochondrial fusion factor mitofusin-2. J Cell Sci. 2005. 118:3153–3161.
Article
58. Szigeti K, Garcia CA, Lupski JR. Charcot-Marie-Tooth disease and related hereditary polyneuropathies: molecular diagnostics determine aspects of medical management. Genet Med. 2006. 8:86–92.
Article
59. Züchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, et al. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol. 2006. 59:276–281.
Article
60. Choi BO, Kim SB, Park KD, Choi KG, Oh J, Suh BC, et al. Clinical and genetic characteristics in patients of Charcot-Marie-Tooth type 2A with mitofusin 2 (MFN2) mutations. J Korean Neurol Assoc. 2006. 24:131–140.
61. Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, Takeda S, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor
KIF1B beta. Cell. 2001. 105:587–597.
Article
62. Bissar-Tadmouri N, Nelis E, Züchner S, Parman Y, Deymeer F, Serdaroglu P, et al. Absence of KIF1B mutation in a large Turkish CMT2A family suggests involvement of a second gene. Neurology. 2004. 62:1522–1525.
Article
63. Muglia M, Zappia M, Timmerman V, Valentino P, Gabriele AL, Conforti FL, et al. Clinical and genetic study of a large Charcot-Marie-Tooth type 2A family from southern Italy. Neurology. 2001. 56:100–103.
Article
64. Verhoeven K, De Jonghe P, Coen K, Verpoorten N, Auer-Grumbach M, Kwon JM, et al. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet. 2003. 72:722–727.
Article
65. Jordens I, Fernandez-Borja M, Marsman M, Dusseljee S, Janssen L, Calafat J, et al. The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors. Curr Biol. 2001. 11:1680–1685.
Article
66. Irobi J, Van Impe K, Seeman P, Jordanova A, Dierick I, Verpoorten N, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet. 2004. 36:597–601.
Article
67. Benndorf R, Welsh MJ. Shocking degeneration. Nat Genet. 2004. 36:547–548.
Article
68. Evgrafov OV, Mersiyanova I, Irobi J, Van Den Bosch L, Dierick I, Leung CL, et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet. 2004. 36:602–606.
Article
69. Sun X, Fontaine JM, Rest JS, Shelden FA, Welsh MJ, Benndorf R. Interaction of human HSP22 (HSPB8) with other small heat shock proteins. J Biol Chem. 2004. 279:2394–2402.
Article
70. Benndorf R, Sun X, Gilmont RR, Biederman KJ, Molloy MP, Goodmurphy CW, et al. HSP22, a new member of the small heat shock protein superfamily, interacts with mimic of phosphorylated HSP27 ((3D)HSP27). J Biol Chem. 2001. 276:26753–26761.
Article
71. Antonellis A, Ellsworth RE, Sambuughin N, Puls I, Abel A, Lee-Lin SQ, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet. 2003. 72:1293–1299.
Article
72. Warner LE, Hilz MJ, Appel SH, Killian JM, Kolodry EH, Karpati G, et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type IB, Déjérine-Sottas, and congenital hypomyelination. Neuron. 1996. 17:451–460.
Article
73. Marrosu MG, Vaccargiu S, Marrosu G, Vannelli A, Cianchetti C, Muntoni F. Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene. Neurology. 1998. 50:1397–1401.
Article
74. Shy ME, Jani A, Krajewski K, Grandis M, Lewis RA, Li J, et al. Phenotypic clustering in MPZ mutations. Brain. 2004. 127:371–384.
Article
75. Hattori N, Yamamoto M, Yoshihara T, Koike H, Nakagawa M, Yoshikawa H, et al. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelinrelated proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain. 2003. 126:134–151.
Article
76. Lemke G, Axel R. Isolation and sequence of a cDNA encoding the major structural protein of peripheral myelin. Cell. 1985. 40:501–508.
Article
77. Xu W, Manichella D, Jiang H, Vallat Jm, Lilien J, Baron P, et al. Absence of P0 leads to the dysregulation of myelin gene expression and myelin morphogenesis. J Neurosci Res. 2000. 60:714–724.
Article
78. Wong MH, Filbin MT. The cytoplasmic domain of the myelin P0 protein influences the adhesive interactions of its extracellular domain. J Cell Biol. 1994. 126:1089–1097.
Article
79. Carter J, Gragerov A, Konvicka K, Elder G, Weinstein H, Lazzarini RA. Neurofilament (NF) assembly; divergent characteristics of human and rodent NF-L subunits. J Biol Chem. 1998. 273:5101–5108.
Article
80. Fabrizi GM, Cavallaro T, Angiari C, Bertolasi L, Cabrini I, Ferrarini M, et al. Giant axon and neurofilament accumulation in Charcot-Marie-Tooth disease type 2E. Neurology. 2004. 62:1429–1431.
Article
81. De Jonghe P, Mersivanova I, Nelis E, Del Favero J, Martin JJ, van Broeckhoven C, et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol. 2001. 49:245–249.
Article
82. Zhu Q, Couillard-Despres S, Julien JP. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp Neurol. 1997. 148:299–316.
Article
83. Kriz J, Zhu Q, Julien JP, Padjen AL. Electrophysiological properties of axons in mice lacking neurofilament subunit genes: disparity between conduction velocity and axon diameter in absence of NF-H. Brain Res. 2000. 885:32–44.
Article
84. Jordanova A, De Jonghe P, Boerkoel CF, Takashima H, De Vriendt E, Ceuterick C, et al. Mutations in the neurofilament light chain gene (
NEFL) cause early onset severe Charcot-Marie-Tooth disease type 1A. Brain. 2003. 126:590–597.
Article
85. Choi BO, Lee MS, Shin SH, Hwang JH, Choi KG, Kim WK, et al. Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients. Hum Mutat. 2004. 24:185–186.
86. Herringham WP. Muscular atrophy of the peroneal type affecting many members of a family. Brain. 1889. 11:230–236.
Article
87. Bergoffen J, Scherer SS, Wang S, Scott MO, Bone LJ, Paul DL, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science. 1993. 262:2039–2042.
Article
88. Birouk N, LeGuern E, Maisonobe T, Rouger H, Gouider R, Tardieu S, et al. X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology. 1998. 50:1074–1082.
Article
89. Hahn AF, Bolton CF, White CM, Brown WF, Tuuha SE, Tan CC, et al. Genotype/phenotype correlations in Xlinked dominant Charcot-Marie-Tooth disease. Ann N Y Acad Sci. 1999. 883:366–382.
Article
90. Fischbeck KH, ar-Rushdi N, Pericak-Vance M, Rozear M, Roses AD, Fryns JP. X-linked neuropathy: gene localization with DNA probes. Ann Neurol. 1986. 20:527–532.
Article
91. Vital A, Ferrer X, Lagueny A, Vandenberghe A, Latour P, Goizet C, et al. Histopathological features of X-linked Charcot-Marie-Tooth disease in 8 patients from 6 families with different connexin32 mutations. J Peripher Nerv Syst. 2001. 6:79–84.
Article
92. Nicholson SM, Gomes D, de Nechaud B, Bruzzone R. Altered gene expression in Schwann cells of connexin32 knockout animals. J Neurosci Res. 2001. 66:23–36.
Article
93. Evans WH, Martin PE. Gap junctions: structure and function. Mol Membr Biol. 2002. 19:121–136.
94. Kumar NM, Gilula NB. Cloning and characterization of human and rat liver cDNAs coding for a gap junction protein. J Cell Biol. 1986. 103:767–776.
Article
95. Scherer SS, Deschenes SM, Xu YT, Grinspan JB, Fischbeck KH, Paul DL. Connexin32 is a myelin-related protein in the PNS and CNS. J Neurosci. 1995. 15:8281–8294.
Article
96. Rozear MP, Pericak-Vance MA, Fischbeck K, Stajich JM, Gaskell PC Jr, Krendel DA, et al. Hereditary motor and sensory neuropathy, X-linked: a half century follow-up. Neurology. 1987. 37:1460–1465.
Article
97. Hahn AF, Brown WF, Koopman WJ, Feasby TE. X-linked dominant hereditary motor and sensory neuropathy. Brain. 1990. 113:1511–1525.
Article
98. Bort S, Nelis E, Timmerman V, Sevilla T, Cruz-Martinez A, Martinez F, et al. Mutational analysis of the MPZ, PMP22 and Cx32 genes in patients of Spanish ancestry with Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies. Hum Genet. 1997. 99:746–754.
Article
99. Silander K, Meretoja P, Juvonen V, Ignatius J, Pihko H, Saarinen A, et al. Spectrum of mutations in Finnish patients with Charcot-Marie-Tooth disease and related neuropathies. Hum Mutat. 1998. 12:59–68.
Article
100. Mersiyanova IV, Ismailov SM, Polyakov AV, Dadali EL, Fedotov VP, Nelis E, et al. Screening for mutations in the peripheral myelin genes
PMP22, MPZ and
Cx32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients. Hum Mutat. 2000. 15:340–347.
Article
101. Mostacciuolo ML, Righetti E, Zortea M, Bosello V, Schiavon F, Vallo L, et al. Charcot-Marie-Tooth disease type 1 and related demyelinating neuropathies: mutation analysis in a large cohort of Italian families. Hum Mutat. 2001. 18:32–41.
Article
102. Huehne K, Benes V, Thiel C, Kraus C, Kress W, Hoeltzenbein M, et al. Novel mutations in the Charcot-Marie-Tooth disease genes
PMP22,
MPZ, and GJB1. Hum Mutat. 2003. 21:100.
Article
103. Yoshihara T, Yamamoto M, Doyu M, Mis KI, Hattori N, Hasegawa Y, et al. Mutations in the peripheral myelin protein zero and connexin32 genes detected by nonisotopic RNase cleavage assay and their phenotypes in Japanese patients with Charcot-Marie-Tooth disease. Hum Mutat. 2000. 16:177–178.
Article
104. Numakura C, Lin C, Ikegami T, Guldberg P, Hayasaka K. Molecular analysis in Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22, MPZ, and Cx32/GJB1 mutations. Hum Mutat. 2002. 20:392–398.
Article
105. Nelis E, Erdem S, Van Den Bergh PY, Belpaire-Dethiou MC, Ceuterick C, Van Gerwen V, et al. Mutations in GDAP1: autosomal recessive CMT with demyelination and axonopathy. Neurology. 2002. 59:1865–1872.
Article
106. Baxter RV, Ben-Othmane K, Rochelle JM, Stajich JE, Hulette C, Dew-Knight S, et al. Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet. 2002. 30:21–22.
Article
107. Cuesta A, Pedrola L, Sevilla T, Garcia-Planells J, Chumillas MJ, Mayordomo F, et al. The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet. 2002. 30:22–25.
Article
108. Asbury AK, Gale MK, Cox SC, Baringer JR, Berg BO. Giant axonal neuropathy - a unique case with segmental neurofilamentous masses. Acta Neuropathol (Berl). 1972. 20:237–247.
Article
109. Bomont P, Cavalier L, Blondeau F, Ben Hamida C, Belal S, Tazir M, et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet. 2000. 26:370–374.
Article
110. Senderek J, Bergmann C, Stendel C, Kirfel J, Verpoorten N, De Jonghe P, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet. 2003. 73:1106–1119.
Article